January 10, 2018
Authored and Edited by Nathan I. North; Lillian R. Phares; Elizabeth D. Ferrill
In Amgen v. Sandoz, No. 2015-1499, the Federal Circuit affirmed the Northern District of California’s decision that Sandoz had not waived its preemption defense and that the Biologics Price Competition and Innovation Act of 2009 (BPCIA) preempted Amgen’s state law claims against Sandoz’s abbreviated biologics license application (aBLA) for filgrastim (marketed as Neupogen® by Amgen).
The district court held that (1) Sandoz did not waive its preemption defense, and (2) Amgen’s state law claims were preempted by the BPCIA. The Federal Circuit affirmed the district court’s decision on the state law claims, but vacated the district court’s decision on the preemption defense. The Supreme Court then heard the appeal and held that the BPCIA did not allow injunctions and that notice could be given before or after receiving FDA approval for a biologic, reversing and vacating the Federal Circuit’s decision.
On remand from the Supreme Court, the Federal Circuit affirmed the district court’s decision that Sandoz did not waive the defense because preemption was a matter of public concern, and Sandoz preserved its right to assert a preemption defense in its answer. The Federal Circuit also held that the state law claims were preempted under field preemption because Congress intended to occupy the field of biologic litigation. Further, the state law claims were preempted under conflict preemption because they conflicted with Congress’s “intricate federal scheme” and designated remedies.
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Conference
Boston Intellectual Property Law Association 4th Annual Symposium
April 10-11, 2024
Boston
Conference
2nd Annual Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities
March 20, 2024
Boston
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.